Cytokinetics Names Muna Bhanji to Board of Directors
February 18 2021 - 7:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that
Muna Bhanji has been appointed to the company’s Board of Directors.
Ms. Bhanji brings more than 30 years of strategic and operational
experience in the biopharmaceutical industry with a proven track
record of commercial leadership, growth and value creation. Ms.
Bhanji built her career at Merck with leadership experiences
spanning US-based sales, marketing and commercial operations, as
well as global franchise business units and global market access
and policy, across a diverse portfolio of medicines and vaccines.
“We are pleased to welcome Muna to our Board,”
said Robert I. Blum, Cytokinetics’ President and Chief Executive
Officer. “As a veteran commercial leader with demonstrated
expertise in institutional and specialty market sectors as well as
innovative commercial models shaped by a focus on value
demonstration and patient access, her guidance relative to our
continued corporate and commercial development should prove
especially valuable. In particular, we look forward to her insights
to inform how our company may best ensure optimal access and
affordability to our potential medicines developed for patients
with devastating diseases of impaired muscle
function.”
Most recently, Ms. Bhanji served as Merck’s
Senior Vice President, Global Market Access and Policy, leading the
organization to enable access and payer reimbursement for the
company’s medicines and vaccines. During her tenure at the company,
Ms. Bhanji has held senior leadership roles of increasing
responsibility overseeing US and global business units, including
sales, marketing, managed care and commercial operations as well as
serving as the Head of Merck’s Oncology and Hospital and Specialty
businesses. Ms. Bhanji is recognized for building and overseeing
industry leading corporate capabilities and developing partnerships
with key stakeholders to ensure equitable access to novel medicines
and vaccines.
In addition to her extensive commercial
leadership roles, she has served on the Board of the Foundation of
Managed Care Pharmacy and has chaired Merck’s Supervisory Board in
the Netherlands. Muna currently serves on the Board of Corus
International, an ensemble of faith-based organizations working in
concert to deliver the holistic, lasting solutions needed to
overcome the interrelated challenges related to poverty and
health.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is preparing for regulatory
interactions for omecamtiv mecarbil, its novel cardiac muscle
activator, following positive results from GALACTIC-HF, a large,
international Phase 3 clinical trial in patients with heart
failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3
clinical trial of omecamtiv mecarbil. Cytokinetics is also
developing CK-274, a next-generation cardiac myosin inhibitor, for
the potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics is also
developing reldesemtiv, a fast skeletal muscle troponin activator
for the potential treatment of ALS and other neuromuscular
indications following conduct of FORTITUDE-ALS and other Phase 2
clinical trials. The company is preparing for the potential
advancement of reldesemtiv to a Phase 3 clinical trial.
Cytokinetics continues its over 20-year history of pioneering
innovation in muscle biology and related pharmacology focused to
diseases of muscle dysfunction and conditions of muscle
weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane
WeiserSenior Vice President, Corporate Communications, Investor
Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024